ArticleJournal of neuro-oncology
Robust ability of IFN-gamma to upregulate class II MHC antigen expression in tumor bearing rat brains.
Article in Journal of neuro-oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- Novel vaccination strategies based on optimal stimulation of CD4Frontiers in immunology · 2024Article
- CXCL16-positive dendritic cells enhance invariant natural killer T cell-dependent IFNγ production and tumor control.Oncoimmunology · 2016Article
- The controversial role of microglia in malignant gliomas.Clinical & developmental immunology · 2013Review
- Acute in vivo exposure to interferon-gamma enables resident brain dendritic cells to become effective antigen presenting cells.Proceedings of the National Academy of Sciences of the United States of America · 2009Article
- Combined yeast-derived beta-glucan with anti-tumor monoclonal antibody for cancer immunotherapy.Experimental and molecular pathology · 2009Review
- Microglial recruitment, activation, and proliferation in response to primary demyelination.The American journal of pathology · 2007Article
- TGF-beta2 inhibition augments the effect of tumor vaccine and improves the survival of animals with pre-established brain tumors.Journal of neuro-oncology · 2007Article
- Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12.Cancer immunology, immunotherapy : CII · 2006Article
- Up-regulation of neuropoiesis generating glial progenitors that infiltrate rat intracranial glioma.Journal of neuro-oncology · 2005Article
- Brain tumor immunotherapy: an immunologist's perspective.Journal of neuro-oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T cells are attractive for delivering therapy to brain tumor, especially disseminated micro-tumor. However, to trigger effector function, tumor antigen must be re-presented to T cells, via major histocompatibility complex (MHC) proteins, at the tumor site. In normal brain, MHC+ antigen-presenting cells (APC) are rare, but abundant after gamma interferon (IFN-gamma) injection. Here we studied tumor-bearing brains. IFN-gamma (or buffer) was injected stereotactically into brains with established tumors from a panel of immunologically varied glioma cell lines, some expressing b-galactosidase as a micro-tumor marker. Four days later, cryostat sections were stained for tumor and MHC proteins. In phosphate-buffered saline-injected controls, class II MHC+ potential APC (microglia, macrophages) were seen only at (some) tumor sites. In rats that received IFN-gamma, class II+ potential APC were widespread, including all actual and potential micro-tumor sites and all tumor-free areas. In the same slides, neither class I nor class II MHC antigen was detected in neural cells or most tumor cells. This MHC pattern favors indirect re-presentation of tumor antigen, by tumor-adjacent APC. The robust response to IFN-gamma might also be exploited in other ways: activated microglia and macrophages can attack tumor directly, and class II+ APC may help mark micro-tumor sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.